Common drug review new combination product : indication : type 2 diabetes mellitus. Ertugliflozin/Metformin fixed-dose combination (Segluromet) Merck Canada Inc / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Drug interactions--Data processing.

Drug interactions.

Drug interactions--Handbooks, manuals, etc.

Physical Description:

1 online resource

Edition:

Final (with redactions).

Place of Publication:

Ottawa, ON : CADTH, 2019.

Summary:

Diabetes mellitus is a metabolic disease that is characterized by persistent elevations in blood glucose (hyperglycemia). This persistent elevated blood glucose causes damage to blood vessels on a microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular (peripheral artery disease, cardiovascular disease) level. Diabetes is one of the most common chronic diseases in Canada. Diabetes Canada estimated there were 3.4 million people (9.3% of the population) with diabetes in 2015 and, by 2025, this number will increase to five million people (12.1%). The objective was to perform a systematic review of the beneficial and harmful effects of ertugliflozin 5 mg and 15 mg tablets in combination with metformin, or metformin and sitagliptin, to improve glycemic control in adult patients with type 2 diabetes mellitus when these therapies, along with diet and exercise, do not provide adequate glycemic control. This review was conducted in tandem with the evaluation of ertugliflozin 5 mg and 15 mg tablets (Steglatro), which includes additional study data and an appraisal of the manufacturer-submitted indirect treatment comparison that are not included in this report.

Notes:

Description based on publisher supplied metadata and other sources.